Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer Chemotherapy and Pharmacology
David PlanchardPaul A Dickinson

Abstract

Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. Osimertinib PK was evaluated to define the dose and dosing interval, whether a fixed-dosing approach can be used globally, and the impact of formulation and food on exposure. AURA (NCT01802632): single- and multiple-dose PK of osimertinib (20-240 mg daily) was determined in patients with advanced NSCLC. Bioavailability study (NCT01951599): single-dose PK of osimertinib (20 mg) was determined in healthy volunteers with administration of capsule, solution, or tablet formulations fasted, and as a tablet in the fed and fasted state. Osimertinib was slowly absorbed and displayed dose-proportional increases in exposure from 20 to 240 mg. Distribution was extensive and clearance low to moderate, resulting in a mean half-life of 48.3 h. Steady state was achieved by 15 days of dosing, consistent with single-dose PK, with a peak-to-trough ratio of 1.6. Two active metabolites circulated at ~10 % of osimertinib exposure. Ethnicity did not appear to affect exposure. Osimertinib PK profiles in healthy volunteers were similar to those in patients a...Continue Reading

References

Mar 3, 2005·Journal of the National Cancer Institute·Hisayuki ShigematsuAdi F Gazdar
Jan 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Cai-Hong YunMichael J Eck
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardVincent A Miller
Jan 21, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria E ArcilaMarc Ladanyi
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Mar 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helena A YuGregory J Riely
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Sep 17, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jong-Mu SunKeunchil Park
Apr 2, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Wei LiGerald Schmid-Bindert
Apr 29, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J L KuiperE F Smit
Apr 30, 2015·The New England Journal of Medicine·Pasi A JänneMalcolm Ranson

❮ Previous
Next ❯

Citations

Jul 30, 2016·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Johannes J M RoodRolf W Sparidans
Oct 25, 2016·Bulletin du cancer·Etienne Giroux LeprieurMarie Wislez
Nov 26, 2016·Expert Review of Clinical Pharmacology·Kenzo SoejimaToshiyuki Hirano
Jan 25, 2017·Expert Opinion on Pharmacotherapy·Jong-Mu SunMyung-Ju Ahn
Dec 24, 2016·British Journal of Clinical Pharmacology·Kathryn BrownEugène Cox
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangPasi A Jänne
Jun 2, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Meredith K BollingerGerard P Mascara
Dec 15, 2017·Journal of Clinical Pharmacology·Hongyun ZhaoLi Zhang
Apr 24, 2018·Clinical Pharmacology in Drug Development·Karthick VishwanathanJo Collier
Oct 24, 2017·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Osamu YasumuroNoriyuki Namiki
Nov 3, 2017·Expert Opinion on Drug Metabolism & Toxicology·Antonio RossiEvaristo Maiello
Sep 2, 2018·British Journal of Clinical Pharmacology·R Donald HarveyKarthick Vishwanathan
Jan 19, 2019·Future Oncology·Jennifer W Carlisle, Suresh S Ramalingam
Apr 2, 2019·Journal of the Chinese Medical Association : JCMA·Hsiang-Ling HoTeh-Ying Chou
Feb 21, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RemonE Felip
Jan 21, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Samantha H SpencerKatherine V Sarna
Dec 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C H YangMyung-Ju Ahn
Jul 16, 2017·Targeted Oncology·Yvette N Lamb, Lesley J Scott
Mar 15, 2018·European Journal of Clinical Pharmacology·Guo YuHong-Hao Zhou
Feb 13, 2018·Oncotarget·Ya-Wen SunWen-Juan Liu
Nov 21, 2018·Expert Opinion on Drug Safety·Laura MezquitaDavid Planchard
Jun 21, 2019·Bioanalysis·Richard MitchellPhillip Turpin
Mar 5, 2020·Clinical Case Reports·Yo KawaguchiTadashi Sugiyama
Jul 4, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Masaaki NaganoHiroyuki Mano
Feb 14, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·A Kenneth MacLeodC Roland Wolf
Jan 14, 2021·International Journal of Molecular Sciences·Agnieszka Rybarczyk-KasiuchniczKatarzyna Stencel
Jan 12, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·B van VeggelA J de Langen
Feb 18, 2021·Expert Opinion on Pharmacotherapy·Luigi CerboneCarlo Genova

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.